Ask AI

Ready, Set, Complement! Novel C5 Inhibitors in Generalized Myasthenia Gravis

Video
This activity is available for 1.00 CME/CE credit(s).

Released: November 20, 2026

Expiration: November 19, 2027

See Activity Collection

Despite advances in treatment, patients with generalized myasthenia gravis may continue to experience symptoms, adverse effects, and treatment-related burdens. Through expert discussion and patient perspectives, this on-demand webcast examines the evolving role of C5 inhibitors, compares available and emerging therapies, and explores strategies for aligning treatment decisions with clinical goals and patient preferences.

C5 Inhibitors in gMG

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with gMG do you provide care for in a typical month?​

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A patient with generalized myasthenia gravis receiving prednisone and azathioprine has had no recent exacerbations. However, persistent fatigable weakness limits work, and prednisone-associated weight gain and insomnia affect daily life.

Which interpretation best characterizes this patient’s unmet treatment needs?

4.

Which statement correctly describes a distinguishing administration and safety consideration for a complement inhibitor approved for use in AChR+ gMG?

5.

A 62-yr-old patient with AChR+ gMG has persistent activity-limiting symptoms despite standard therapy. After discussing C5 inhibitors, the patient prefers infrequent clinic infusions over daily self-injections because of hand weakness. Insurance coverage is comparable.

Which plan best incorporates this patient’s preferences and long-term care needs?